5AM Partners VI, LLC - Jul 18, 2024 Form 3 Insider Report for Artiva Biotherapeutics, Inc. (ARTV)

Role
10%+ Owner
Signature
5AM Ventures VI, L.P., By: 5AM Partners VI, LLC, its General Partner, By /s/ Kush Parmar, Managing Member
Stock symbol
ARTV
Transactions as of
Jul 18, 2024
Transactions value $
$0
Form type
3
Date filed
7/18/2024, 08:06 PM
Previous filing
Feb 16, 2024
Next filing
Jul 24, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ARTV Series A Preferred Stock Jul 18, 2024 Common Stock 844K By 5AM Ventures VI, L.P. F1, F2
holding ARTV Series B Preferred Stock Jul 18, 2024 Common Stock 215K By 5AM Ventures VI, L.P. F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") is convertible into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering, the Preferred Stock will convert into the number of shares of Common Stock of the Issuer shown in column 3. The Preferred Stock has no expiration date.
F2 The shares are directly held by 5AM Ventures VI, L.P. ("Ventures VI"). 5AM Partners VI, LLC ("Partners VI") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein.